Medical Devices & Tech

DiagnoCure

2050 Rene-Levesque Blvd W., 6th Floor
Quebec, QC G1V 2K8 Canada
Phone
Fax
Click for website

Research Sector Medical Devices & Tech

Summary Description Develops diagnostic tests for cancer detection and management

Management John C. Schafer, President and Chief Executive Officer; Jean-Fran?ois Bureau, CFA, Senior Vice President and Chief Financial Officer; Dr Yves Fradet, Senior Vice President and Chief Medical Officer; Paule De Blois, Vice President, Corporate Affairs; Richard Gauthier, Vice President, Business Development; Timothy J. Holzer, Vice President and Chief Scientific Officer; Phillip Wells, Vice President, Marketing and National Sales

Click here for Financial Data
Keywords: diagnostics, urology, advamed, Colorectal Cancer, GCC, PrevistageTM GCC, Molecular diagnostic tests, Prostate cancer, PCA3

Comment


Updated: Sept. 11, 2014


Description

DiagnoCure develops and commercializes tests and lab services facilitating cancer detection and diagnosis. The company specializes in molecular tests that detect irregular gene or protein activity pat......view more

Products / Services

DiagnoCure first entered the bladder cancer market with Immunocyt(TM)/uCyt+(TM), a non-invasive test for superficial bladder cancer detection. Its latest product pipeline includes: the PCA3 prostate c......view more

Technology / Differentiation

Compared to traditional pathology methods, which can detect one cancer cell in 200 normal cells, molecular technologies can detect one cancer cell in up to 10 million normal cells. This represents a s...view more

Market / Customers

Prostate cancer is the most frequent cancer and second leading cause of cancer death in men, representing an estimated market of 1.8 million tests per year in North America and Europe. Colorectal canc......view more


Status

ImmunoCyt (TM) has FDA clearance for commercialization in the United States for the monitoring of bladder cancer. DiagnoCure launched its Previstage(TM) GCC Colorectal Cancer Staging Test in August 20...view more

RELATED COMPANIES



0000-00-00-6129